Biopharmaceuticals
The latest news about Biopharmaceuticals: headlines, AI summaries and the full story from every source.
- OrthoTrophix Reports Data Suggesting TPX-100 May Slow Knee Osteoarthritis Progression
- Emergent BioSolutions Updates Revenue Guidance and Implements Cost-Cutting Measures
- AstraZeneca Reports Q3 2026 Results with Strong Oncology and Rare Disease Growth
- AbbVie Successfully Transitions Revenue from Humira to New Immunology and Neuroscience Growth Engines
- Xencor Shares Rise 16% Following Positive Early Clinical Data for XmAb819
- Verastem Oncology Announces New CEO Appointment and $250M Securities Offering
- Teva CEO Outlines Biopharma Strategy and $700M Cost-Saving Plan
- ABEC Expands Manufacturing Network With New Facility in Wilson, North Carolina
- Alnylam Pharmaceuticals Underperformed Amid Clinical Trial Concerns
- Meridian Small Cap Growth Fund Highlights Definium Therapeutics (DFTX) for Mental Health Innovation
- Gilead Sciences to Report Q2 Earnings Amid Analyst Expectations of Loss
- Samsung Biologics Acquires PolyPeptide Group in $1.8 Billion Deal
- AtaiBeckley Surges Following Eli Lilly's Acquisition Offer Worth Up to $3.8 Billion
- Sagimet Biosciences Inclusion in Russell Indexes Sparks Investor Interest
- Mizuho Maintains Outperform Rating on Insmed (INSM) Despite Lowered Price Target
- Biopharma M&A Activity Surges as Patent Cliff Drives Deal-Making
- Nan Fung Group Sells $4.3 Million Worth of Oculis Shares Amid Drug Trial Setback
- RBC Capital Raises Price Target on Neurocrine Biosciences
- Maxim Upgrades Gilead Sciences (GILD) to 'Buy'
- JPMorgan Increases Price Target for Xenon Pharmaceuticals
- Prosight Management Invests $10.27 Million in Nektar Therapeutics Ahead of Key Phase 3 Launch
- Prosight Management Invests $10 Million in Nektar Therapeutics Ahead of Key Phase 3 Launch
- Bristol-Myers Squibb Ends Six-Day Winning Streak
- MannKind Corp Reports Q1 2026 Total Revenues of $90.2 Million
- Canaccord Maintains Buy Rating on Compass Therapeutics Despite Lowered Price Target
- Axsome Therapeutics Stock Surges on FDA Approval and Positive Earnings Report
- Raymond James Initiates Coverage on Insmed with Outperform Rating
- Oruka Therapeutics Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001